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ABSTRACT
It has been well established that low-density lipoproteins (LDL) and other apolipoprotein
B-containing lipoproteins are causally related to atherosclerotic cardiovascular disease
(ASCVD) and that lowering these lipoproteins reduces the risk of ASCVD. By lowering LDL
particles as much as possible, ASCVD can be prevented. There seems to be no LDL-cholesterol
(LDL-C) threshold below which no further ASCVD prevention can be achieved. Furthermore,
a low (an even very low) LDL-C appears to be safe. The new ESC/EAS guidelines based on these
concepts are a step towards a bene!t-based strategy by focusing on the clinical bene!t that
can be achieved by treating the cause of ASCVD. It is recommended to lower LDL-C as much as
possible to prevent ASCVD, especially in high and very high-risk patients. With these new
recommendations come recognition of the importance of combination therapies in high and
very high-risk patients, !rst with statins and ezetimibe, and if needed with a PCSK9 inhibitor.
The present paper is a review of some new concepts arising during the past 10 years in the !eld






Major basic concepts developed during the
past 10 years
LDL is a causal risk factor
It has been well established that the association
between LDL-C and ASCVD is not only statistically
signi!cant but that it is causal in origin (Figure 1) [1].
In medicine, the scienti!c evidence of a causal link
between a factor and a disease is based on a number
of criteria (called the ‘Bradford-Hill criteria’) including
the strength of the association, the reversibility of risk
through reduction of the factor by intervention, the
time sequence where the factor precedes the disease,
the reproducibility of the evidence (studies must be
repeated many times and on large cohorts) and the
consistency between di"erent approaches. Regarding
the strength of association, countless data from human
epidemiological observations and their meta-analyses
show the very strong link between high LDL-C levels
and the risk of ASCVD [2].
Subsequently, in numerous randomized controlled
trials and in their meta-analyses [3] it has been shown
that the reduction of LDL-C with statins or with statins
in combination with other LDL-C-lowering drugs leads
to a reduction in the incidence of ASCVD. Data from
genetic models of hypercholesterolemia such as famil-
ial hypercholesterolemia (FH) show the dangerous nat-
ure of carrying very high levels of LDL-C from birth
onwards.
Finally, the study of genetic variants, more frequent
but less severe than FH (polymorphisms in genes
involved in the production, absorption and elimination
of cholesterol), in Mendelian randomization studies
shows that small variations in LDL-C (e.g. 11 mg/dL
for one variant of NPC1L1, the gene of the protein
participating to the intestinal absorption of choles-
terol) from birth onwards are su#cient to signi!cantly
reduce the risk of cardiovascular (CV) events through-
out life (in this example, by 20%). Mechanistically, the
pathogenesis of atherosclerosis is very well under-
stood as illustrated in Figure 1.
Thus, all these observations (strong association, CV
bene!t of therapeutic interventions that reduce LDL-C
and time sequence con!rmed by genetics) converge
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on the idea that there is indeed a causal link between
LDL particles and ASCVD and that the reduction of LDL
is e"ective in signi!cantly reducing the risk of ASCVD.
That results in proclaiming LDL-C level as a primary
target for ASCVD prevention.
In contrast, the same approaches (intervention trials
with drugs speci!cally able to increase HDL cholesterol
(HDL-C) and Mendelian randomization genetic studies)
were not able to show a causal link between HDL-C and
ASCVD [4]. While remaining a ‘marker’ of risk (because it
helps to estimate the total cardiovascular risk), the HDL-C
level is not targeted in prevention strategies. Regarding
triglycerides, the association with ASCVD exists but no
target is set because the association becomes null after
adjustment for non-HDL-cholesterol (non-HDL-C) which
is an estimate of the concentration of all apo
B-containing lipoproteins (Figure 1).
There is no lower limit for LDL cholesterol
A question that arises from the causal association of
LDL with ASCVD is ‘how low can we get for LDL-C and
is there an LDL-C threshold for clinical bene!t?’. The
LDL-C limit (also called ‘target’) recommended in the
past guidelines has evolved quite a lot over time.
A quarter of a century ago, the 4S trial was the !rst
modern trial on lipid-based ASCVD prevention in
patients with established coronary disease [5]. These
patients had high levels of LDL-C (around 190 mg/dL)
and the reduction of LDL-C to the normal range
(around 120 mg/dL) was associated with a signi!cant
bene!t in terms of all-cause mortality and major cor-
onary event. This allowed to conclude that ‘high is bad’
and that a reduction of high levels with simvastatin
was e"ective and safe. The next question was then:
“Should we also lower LDL-C in individuals with so-
called average levels of LDL-C?” The idea that average
(‘normal’ in terms of population distribution) is not
‘appropriate’ for the arterial wall was a tricky concept,
di"erent from what we know from many biological
variables where the average level in the general popu-
lation is the ideal level for health. A series of trials like
‘CARE’ [6] and ‘the Heart Protection Study’ [7] were




















Small & dense LDL
A. Simple causal link
B. Indirect causal link
C. No causal link
D. Pathogenesis
E. Small dense LDL genesis and non HDL cholesterol
Atherogenic cholesterol = Total Chol. – HDL Chol.
= Non HDL cholesterol
Figure 1. Causal relationship between lipid parameters and atherosclerotic cardiovascular disease (ASCVD).
The panels A-C show the di!erent relationships between the common lipids parameters and ASCVD. The panel D is a scheme of the pathogenesis of
atherosclerosis where the "rst step is the retention in the artery wall of LDL (and other apoB-containing lipoproteins) followed by the cascade of oxidation,
macrophages and lymphocytes migration, in#ammation, smooth cell proliferation that cause atherosclerosis, and later on arterial stenosis, plaque disruption
and embolization leading to acute or chronic coronary, cerebrovascular or peripheral ischaemia. Panel E. Genesis of small dense LDL: the presence of high level
of triglycerides (Tg.) is associated to high levels of Tg-rich VLDL which can undergo transfer (through the enzymatic activity of CETP) of their Tg to LDL (less rich
in TG) in exchange of the cholesterol of LDL (richer in cholesterol) to VLDL (poor in cholesterol). The hydrolysis of Tg (i.e. by hepatic lipase) in these Tg-enriched
/cholesterol-depleted LDL, gives rise to small dense LDL.
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with average levels of LDL-C (around 120–150 mg/dL).
The signi!cant bene!t demonstrated in achieving LDL-
C less than 100 mg/dl in these patients demonstrated
that “average is not good” and supported the new
target of <115 mg/dL in the 1998 European guidelines
[8] then <100 mg/dl in the 2003 European guide-
lines [9].
Subsequent trials like ‘PROVE IT’ [10] and ‘TNT’ [11]
comparing high-intensity statin therapy (i.e. atorvasta-
tin 80 mg) with low-intensity therapy (i.e. pravastatin
40 mg) have showed undoubtfully that achieving LDL-
C to <70 mg/dL is further associated with a reduction
in ASCVD events. Meanwhile, the Cholesterol
Treatment Trialists (CTT) Collaboration meta-analysis
demonstrated that the ASCVD bene!t is linearly corre-
lated with the reduction of LDL-C so that this could be
expressed by a ‘rule’: each reduction of LDL-C by
40 mg/dL is associated with a relative reduction in
ASCVD events of 20% [3]. The message becomes thus
‘Lower is better’ or ‘Even more intensive LDL lowering
is better’ which supported the concept of high-
intensity statin therapy. So, in 2011, lipid guidelines
issued an update recommending LDL-C target at
<70 mg/dL in patients at very high total CV risk [12]
and this remained at that level in the 2016 guide-
lines [13].
Then, in 2016, were published the results from the
‘IMPROVE IT’ trial where LDL-C was further lowered by
adding ezetimibe on top of a statin in patients with
established ASCVD in whom the LDL-C was >70 mg/dL
[14]. With this combination an LDL-C around 55 mg/dL
was achieved and this resulted in more ASCVD preven-
tion suggesting that ‘even lower is even better’ and
that combining statin therapy with a cholesterol
absorption inhibitor is bene!cial and safe.
That has set the rationale for an LDL-C target even
lower than <70 mg/dL. This has been tested in the
most recent clinical trials, ‘FOURIER’ and ‘ODYSSEY
OUTCOMES’ with the monoclonal antibodies against
PCSK9 given in very high-risk patients with LDL-C
around 70 mg/dL despite optimally treated with statin
[15,16]. The further reduction of LDL-C to a very low
level (40 mg/dL and less) resulted in 15–20% reduction
in major CV events. Importantly, sub-analyses of these
trials supported the hypothesis that there appeared to
be no LDL-C threshold for clinical bene!t and no risk
related to achieving ‘very very low’ levels. A FOURIER
sub-analysis [17] that examined the results in terms of
achieved LDL-C demonstrated a monotonic nearly lin-
ear relationship between achieved LDL-C and the risk
of major CV events (CVD death, MI or stroke) till levels
as low as 20 mg/dL. Interestingly the shape of this
linear curve is similar to the relationship between the
achieved LDL-C and the change of the coronary plaque
volume measured by IVUS in the GLAGOV trial [18]
where patients were randomized to receive PCSK9
inhibitors versus placebo on top of a statin. Results
from the GLAGOV trial con!rmed a critical LDL-C level
(between 70 and 90 mg/dL), already pointed out in
previous IVUS trials [19], where the plaques grow if the
achieved LDL-C is above that level and plaques regress
if below that level. The similarity between the curves
underpins the mechanistic process behind prevention:
to prevent a ASCVD event, plaques need to shrink, and
that can be achieved by lowering LDL-C below
70–90 mg/dL. Another FOURIER sub-analysis [20]
examined the subgroup of patients with baseline
LDL-C less than 70 mg/dL (N = 2034; median 66 mg/
dL), a level where according to previous guidelines, it
was not clear to reduce that level further. Under PCSK9
inhibitors, they achieved a median LDL-C of 21 mg/dL
(IQR 11,5–37, which means that a quarter had LDL-C
below 11,5 mg/dL) and the relative bene!t was just as
great as in those who had higher levels of LDL-C to
start with .
So, this clari!es the idea that we should treat the
patients at very high total ASCVD risk with the rule
‘Lowest is better’. That was con!rmed in a more recent
meta-analysis of the subgroups of patient starting with
LDL-C levels averaging 70 mg/dL or less in various
statin and non-statin trials [21]: the risk of major vas-
cular events is signi!cantly reduced by 21% for
38.7 mg/dL (after adjustment) reduction in LDL-C,
which is virtually of the same magnitude as what was
observed in the Cholesterol Treatment Trialists
Collaboration analysis in which the starting LDL-C
was nearly twice as high.
Treat earlier
Another question that arises from the causal associa-
tion of LDL with ASCVD is ‘What if we lower LDL-C
earlier in life?’. Knowledge of the impact of lifelong
exposure to lower LDL-C levels on future risk for
ASCVD has been driven largely by insights from
Mendelian randomisation studies [22–24]. Individuals
with genetic variants lowering even slightly LDL-C
levels compared to the general population have
a strong lifelong CV risk reduction. This may suggest
that treating more persons earlier in life with even less
intensive therapy could ultimately lead to more pre-
vention of ASCVD at the population level [25].
The concept of lifelong cholesterol burden is a little
bit like smoking where we think about ‘pack years’:
someone who had smoked 2 packs a day for 20 years
has a 40 pack-year smoking history. The same concept
can apply for LDL-C. This is illustrated in Figure 2,
where the X-axis is the lifetime, the Y-axis their cumu-
lative amount of LDL-C. The slope of the line is simply
a function of the circulating level of LDL-C. With an
average level of LDL-C (around 120 mg/dL), the line
will reach at age 70 the red line which is the threshold
for ASCVD (arbitrarily drawn here, as it will vary from
person to person depending on other risk factors
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predisposing to ASCVD such as hypertension, diabetes
and smoking). Some people are genetically at risk, for
example, those having heterozygous familial hyperch-
olesterolemia (HeFH, with a steeper blue line) with
LDL-C levels around 250 mg/dL (or worse for the rare
homozygous FH) and they will get to the threshold for
ASCVD earlier so they’ll develop clinical events prema-
turely. Others are genetically protected, for example,
those who have a PCSK9 loss of function variant at the
heterozygous state (with a $atter green line) with LDL-
C levels around 85 mg/dL and they will be protected
from developing ASCVD. There is little debate about
treating people with HeFH early as they are at very
high risk and as there is evidence that treating them
early, will delay the onset of ASCVD and thus shift their
curve to the right. What about average individuals?
Typically, our guidelines have been tethered to the
notion of 10-year risk and because age is the ultimate
driver for risk, it’s very hard to have a high 10-year risk
until one is in its mid 50s. That means however that we
are neglecting all the time that arteries may be
exposed to high levels of LDL-C, leading to subclinical
atherosclerosis. If we start treating in the 50s, it is very
hard to bend the curve in Figure 2. What would hap-
pen if we treat them earlier (in the 20s) and reduce
their LDL-C by 40%? Doing this, the slope of their curve
can really be changed (the dotted green line); in other
words, they should be greatly protected from coronary
disease as it happens in the carriers of loss of function
PCSK9 variant who have a 80% lifelong reduction of
ASCVD with a delay of onset to about 30 years. This is
further supported in a recent observational study [26]
comparing coronary artery calcium (CAC) in the Multi-
Ethnic Study of Atherosclerosis (MESA) population in
the United States (where average LDL-C is around
120 mg/dL) with the “Tsimane population“ (a prein-
dustrial society in the Bolivian Amazon who have an
average LDL-C of 75 mg/dL). The 40% LDL cholesterol
reduction between these two populations (75 versus
120 mg/dL) shifts the burden of atherosclerosis by
approximately 30 years.
The end of some misconceptions
It is interesting to point out how these recent !ndings
have explicitly rejected a number of concepts that have
beenpromoted in thepast and are sometimes subjected
to polemics.
The !rst misconception is that HDL cholesterol is the
good cholesterol and LDL cholesterol is the bad one.
A lowHDL-C level indicates the presence of other under-
lying ASCVD risk factors like insulin-resistance, lack of
physical activity, excess of blood triglycerides or others.
As it somehow quanti!es these underlying disorders,
HDL-C remains a good risk marker for the estimation of
the total CVD risk. However, drug therapies that
increased the HDL-C levels failed to demonstrate risk
reduction. Therefore, HDL-C is not a target for therapy
and treatment should therefore focus on correcting the
underlying cause of low HDL-C.
LDL but also other apoB-containing lipoproteins
(VLDL and IDL) causes atherosclerosis. So, the new
2019 ESC/EAS guidelines emphasizes the use of the
level of apolipoprotein B or, if not available, the ‘non-
HDL-C level’ as secondary targets. The ‘non-HDL-C’ level
takes into account the cholesterol of all of the athero-
genic apoB-containing lipoproteins: LDL, small dense
LDL, IDL and VLDL and lipoprotein(a) (Figure 1). It
appears to be more stable over time than triglyceride
levels in practice and is well correlated with the inci-
dence of ASCVD. It is thus used as secondary target (or
even primary target if triglycerides exceed 400 mg/dL
rendering the LDL-C countless by the Friedewald for-
mula) especially in patients with elevated triglycerides,
with metabolic syndrome or with diabetes [27].
The second misconception is that the level of LDL-C
(or apoB or non-HDL-C) does not improve risk predic-
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Figure 2. E!ect of lifelong exposure of LDL cholesterol and the e!ect of LDL lowering therapy at various ages.
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apoB-containing lipoproteins cause ASCVD. However,
adding LDL to a risk prediction model does not
improve its discrimination. This is largely an artifact of
a mathematical dominance of age in most of the cur-
rent risk models. Indeed, one could add any risk factor
(smoking, blood pressure, calcium score or polygenic
risk score with hazard ratio more than one) and none
of those would improve the discrimination because of
this mathematical dominance of age. So to overcome
this dominance of age, the new 2019 ESC/EAS guide-
lines speci!cally suggest a nuanced approach for risk
assessment especially for younger and older indivi-
duals (see below).
The third misconception is that statins are somehow
magical and reduce risk by doing other things (the so-
called ‘pleiotropic e"ect’) than lowering LDL-C. In the
trials, if we plot the PCSK9 trials or the ezetimibe trial on
the cholesterol treatment trials regression line (eventually
rede!ned by duration of follow up), the points are exactly
on the same linewhatever the drugs used to lower LDL-C.
In Mendelian randomization studies, we see that the
variances in the HMG Co reductase gene, in the PCSK9
gene and in the NPC1L1 gene that mimic respectively
statins, PCSK9 inhibitors and ezetimibe are associated
with the same reduction in the risk of ASCVD per any
change in LDL-C. So, the new 2019 ESC/EAS guidelines
explicitly reject the mythology of statins by suggesting
that we should move away from the recommendation of
high-intensity statins towards high-intensity lipid-
lowering therapy.
The fourth misconception is that the bene!t of LDL
lowering therapy (statins in particular) is largely indepen-
dent of baseline LDL levels. That is amisconception based
on the past idea that it is the percent reduction in LDL-C
that drives the bene!t. The cholesterol treatment trial
(CTT) regression line shows that the clinical bene!t is in
reality determinedby the absolute reduction in LDL-C, the
same relative risk reduction is produced from the same
Intensity of lipid lowering treatment
Treatment                                       Average LDL-C reduction
Moderate intensity statin ! 30 %
High intensity statin ! 50 %
High intensity statin plus ezetimibe ! 65 %
PCSK9 inhibitor ! 60 %
PCSK9 inhibitor plus moderate intensity statin ! 75 %
PCSK9 inhibitor plus high intensity statin plus 
ezetimibe
! 85 %
% reduction LDL-C Baseline LDL-C
Absolute reduction LDL-C
Relative risk reduction Baseline risk
Absolute risk reduction
Figure 3. How to calculate the bene"t from a lipid-lowering intervention.
The guidelines declare that the bene"t on lipid-lowering therapy is directly proportional to the absolute change in LDL and other apoB-containing
lipoproteins but that this absolute change must be interpreted in the context of somebody’s baseline level of risk. Indeed, the intensity of lipid-lowering
therapy whether it’s a statin, ezetimibe or PCSK9 inhibitors or some combination determines an expected percentage of reduction of LDL. That percentage
of reduction of LDL-C multiplied by the baseline LDL-cholesterol level determines the absolute reduction in LDL cholesterol. As shown by the cholesterol
treatment trial data, it is the absolute reduction of LDL-C that determines the expected clinical bene"t expressed in relative risk reduction with the
following rule: 20% reduction in CV events per 40 mg/dL LDL-C. We can thus multiply the relative risk reduction calculated from this rule by the baseline
risk in order to estimate the expected absolute risk reduction from any lipid-lowering therapy (adapted from Mach et al. ESC/EAS guidelines for the
management of dyslipidaemias: lipid modi"cation to reduce cardiovascular risk. Eur Heart J. 2019 Aug 31. pii: ehz455. doi: 10.1093/eurheartj/ehz455).
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absolute reduction in LDL-C regardless of the baseline
LDL-C. So, the new2019 ESC/EASguidelines nowpropose
a simple algorithm in order to anticipate the expected
clinical bene!t of any lipid-lowering therapy based on the
intensity of therapy and the baseline LDL-C and the base-
line risk (Figure 3). As we can extrapolate from this algo-
rithm, the higher the patients baseline risk and/or the
greater the LDL reduction, the fewer patients you need
to treat to prevent one event (NNT).
What is new in the 2019 ESC/EAS guidelines
The fundamental concepts summarized above have
formed the basis of the new 2019 ESC/EAS guidelines
[28]. Guidelines establish paradigms based on the
existing evidence and then scientists test and extend
those paradigms to determine whether they are cor-
rect and determine where we need to go next. And
then as we go through this cycle, the guidelines are
revised and updated based on the available evidence.
For the ASCVD prevention guidelines, we’ve seen pro-
gressively a shift in the paradigms on how to reduce CV
risk, moving from just simple risk factor level-based
treatments, to global CV risk assessment-based
approaches and now, as for the new-released 2019
ESC/EAS lipid guidelines [28], increasingly thinking
more about bene!t-based approaches with the notion
of maximising expected bene!t rather than simply
treating the risks.
To do so, the guidelines recommend to start with
a comprehensive assessment of the total risk of devel-
oping ASCVD in order to titrate the intensity of the
prevention strategy in accordance with the baseline
LDL-C level and the baseline total risk of ASCVD. The
guidelines prioritize the identi!cation of people at
high or very high 10-year risk of experiencing a fatal
cardiovascular event because they are most likely to
derive the greatest short-term clinical bene!t from
aggressively lipid lowering therapy; but recommenda-
tions also emphasize the need to pay attention to
intermediate and low-risk subjects, especially those in
which risk modi!ers will mitigate the risk to a higher
lifelong ASCVD risk.
Comprehensive assessment of ASCVD risk and
classi!cation in four risk categories
The guidelines recommend that we begin with
a comprehensive assessment of ASCVD risk which pro-
ceed in three stages (all at the IC level of class of
recommendation and level of evidence).
1. Risk assessment begins with a thorough clinical
evaluation to identify those clinical situations that are
associated with a high short-term risk of events.
The very high-risk category includes patients who
have documented ASCVD either clinical or unequivo-
cal on imaging. These are patients with a personal
history of an acute coronary syndrome, stable angina,
coronary revascularization, stroke or TIA and peripheral
arterial disease and patients in whom a signi!cant pla-
que has been found in the coronaries or in the carotid
arteries. In addition, other clinical characteristics that
de!ne a very high-risk patient are diabetes (PLUS end
organ damage or 3 or more risk factors or early onset
and long duration of diabetes), severe chronic kidney
disease (CKD) (de!ned as an estimated GFR<30 ml/
min/1.73m2), familial hypercholesterolemia (PLUS
either ASCVD or another major risk factor).
The high-risk category includes patients who have
markedly elevated single risk factor levels (most nota-
bly total cholesterol >310 mg/dL, LDL-C > 190 mg/dL
or blood pressure >180/110 mmHg). Other clinical
characteristics include familial hypercholesterolemia
(but without other risk factors), diabetes (without end
organ damage, with duration of diabetes !10 years or
with another additional risk factor) or moderate CKD
(30 to 60 ml/min/1.73 m2).
The clinical characteristics that de!ne personswho are
at moderate risk are younger patients with diabetes (<35
yrs with type 1 diabetes or <50 yrs with type 2 diabetes)
with duration of diabetes less than 10 years but no other
major risk factors.
2. Next, if the patients do not have these clinical
characteristics, the recommendation is to use the
SCORE model to estimate the 10-year risk of fatal
CVD. The SCORE algorithm is an extremely intuitive
and easy to understand metric that is presented in
men and women separately at di"erent ages and
focuses on the three most important modi!able causes
of atherosclerosis: LDL and apoB-containing lipopro-
teins estimated by total cholesterol, systolic blood
pressure and smoking. The SCORE allows to classify
the individuals into the four categories of very high
risk (calculated SCORE for 10-year risk of fatal CVD !
10%), high risk (!5%), moderate risk (!1%) and low risk
(<1%). The SCORE charts that are now presented in the
2019 guidelines di"er slightly from previous ones
because now interactions between age and the asso-
ciations between the major risk factors and ASCVD
have been taken into account; the new charts also
have results for persons aged 70+.
3. Finally, it is recommended to re!ne and indivi-
dualise the risk estimation by taking into account ‘risk
modi!ers’ that are not captured in the risk algorithms.
This is particularly true for persons who are at mod-
erate risk according to SCORE. In those individuals,
the consideration of risk modi!ers may move up or
down the total CVD risk estimate (and thus the risk
category) and this will in$uence the choice of the
preventive approach. One of these modi!ers, particu-
larly in women, is HDL-C level. Currently in Belgium,
we are using the SCORE recalibrated on Belgian epi-
demiological data [29] and we can use multipliers to
nuance the 10-year risk estimate as a function of HDL-
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C level [30]. For example, a 60-year-old woman who is
a smoker, has SBP of 140 mmHg and total cholesterol
of 230 mg/dL may have an estimated 10-year risk
varying from 2 to 10, thus a moderate risk to a very
high risk, if her HDL cholesterol varies between 80
and 20 mg/dL. The other most important of those risk
modi!ers is a family history of premature athero-
sclerosis; others that should be considered are trigly-
ceride levels, Lp(a), social deprivation, lack of physical
activity, obesity and central obesity, chronic immune-
mediated in$ammatory disorders, major psychiatric
disorders, HIV treatment, obstructive sleep apnea
and non-alcoholic fatty liver disease. And then if
uncertainty remains especially in persons at moderate
risk according to SCORE, it is recommended to search
for subclinical atherosclerosis using non-invasive CV
imaging. Coronary artery calci!cation (CAC) scoring is
clearly the best indicator of making better decisions.
And that happens because half people with
a moderate risk have a CAC score of 0 which reclas-
si!es them to a much lower risk estimate. As shown in
the study of Nazir et al. [31], people with moderate
risk but a CAC score of zero don’t achieve the bene!t
threshold (bene!t over harm) over 10 years of follow-
up whereas people above CAC score of 100 clearly do.
So the speci!c recommendation is to defer therapy in
patients with the CAC score of 0.
It’s important to recognise that risk estimating
equations have a number of limitations. The most
important is that it is mathematically dominated by
age. Importantly age is not a risk factor for ASCVD
but is merely a metric of the cumulative exposure to
lifetime burden of those factors that cause
atherosclerosis.
The SCORE model almost uniformly underestimates
the risk of cardiovascular disease in younger patients.
A 40-year-old man even if he smokes, if he has a very
long lifetime exposure of causal LDL and an elevated
blood pressure will be classi!ed at low or moderate risk
of ASCVD. In these young patients, to contextualize that
information can be done by explaining to the patient that
the short-term risks may be fairly low based on the
equation, but, simply by virtue of their risk factor combi-
nation, that he has !rst a high ‘relative risk’ compared
with other people of his age and that he has secondly the
same risk as a 65-year-old man with ideal risk factors
(non-smoker, total cholesterol <160 mg/dL and SBP <
120 mmHg). This so-called ‘risk age concept’ may be
a particularly motivating metric to change lifestyle.
Due to the mathematical dominance of age within
all risk estimating equations, nearly all men and
women above 70 years old are classi!ed as high or
very high risk. Because of the aggressive goals for LDL
reduction among people with high and very high risk,
it is thus particularly important to contextualise this
information by considering other risk modi!ers. For
example, atherosclerotic imaging may identify those
people who may be less vulnerable or have had low
lifetime exposures to the combination of LDL, SBP and
smoking.
New LDL-cholesterol target in all risk categories
The new guidelines reinforce the idea that LDL-C levels
should be lowered as much as possible to prevent
ASCVD, especially in high and very high-risk patients
(Table 1).
High and very high-risk patients
Very high-risk patients (in both primary and secondary
prevention) should achieve an LDL-C level of <55 mg/
dL and at least a 50% reduction from the baseline LDL-
C level, high-risk patients an LDL-C level of <70 mg/dL
and at least a 50% reduction from the baseline LDL_C
level. Compared to the last guidelines the wording ‘OR’
had been replaced by ‘AND’ to make clear that what
counts is the amplitude of reduction (‘Lower is better’)
as well as the achievement of the lowest target as
possible (‘Lowest is better’). Results from subgroup
analyses of trials with ezetimibe [32] and with PCSK9
inhibitors [33–37] also demonstrate that amongst
patients with extremely elevated ASCVD risk an even
lower LDL-C goal may be considered. This has resulted
in a recommendation (class IIb) that for patients with
ASCVD who experience a second vascular event within
2 years (not necessarily of the same type as the !rst
event) while taking maximally tolerated statin-based
Table 1. Comparison of the LDL-C treatment goals in the subgroups of total CV risk in the ESC/EAS guidelines from 2016 to 2019
(adapted from Mach et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modi"cation to reduce cardiovascular
risk. Eur Heart J. 2019 Aug 31. pii: ehz455. doi: 10.1093/eurheartj/ehz455).









or >50% !a if baseline LDL-C 100–200 mg/dL
<70 mg/dL
and >50% !a
Moderate-risk <115 mg/dL <100 mg/dL
Low-risk <115 mg/dL <115 mg/dL
a Reduction from the untreated baseline LDL-C level.
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therapy, an LDL-C goal of <40 mg/dL may be
considered.
To achieve such low LDL-C goals, the guidelines
emphasize the importance of combination treatment,
combining high-intensity statins with ezetimibe. If the
LDL-C goal is not achieved after 4–6 weeks despite
maximally tolerated statin therapy and ezetimibe,
a PCSK9 inhibitor is recommended.
Low- and intermediate-risk people
In these people, the ESC/EAS guidelines recommend
reinforcing the lifestyle change and suggest the use of
lipid-lowering drugs to lower LDL-C in those with other
quali!ers that put them at a higher total CVD risk (see
above). It is important to note that the new LDL-C
target of <100 mg/dl in intermediate-risk individuals
can be a di#cult target to achieve with lifestyle alone
taking into account the average Belgian LDL-C of
130 mg/dl. Furthermore, the recommendation for
lipid-lowering drugs in the intermediate-risk group
has been upgraded from ‘could be considered’ to
‘should be considered’. Whilst this is a very large
group of individuals in which lipid-lowering therapy
should now be considered, this is scienti!cally sound
and re$ective of the potential bene!ts at the popula-
tion level.
Treatment of dyslipidaemia in older patients
Treatment with statins is recommended for primary
prevention, according to the level of risk, in older
people aged "75. A statin may be considered for pri-
mary prevention in older people aged >75. Particularly
in these older patients, statin treatment should be
started at a low dose specially if there is signi!cant
renal impairment and/or if there is potential for drug
interactions, and then titrated upwards to achieve the
LDL-C treatment goal.
In a recent publication from the CTT collaboration, it
is shown that in the 65–70+ years old, the patients
should keep their statin if there was an earlier indica-
tion [38].
News on other lipid parameters: triglycerides and
lipoprotein(a)
While statin treatment remains the !rst choice for
managing high triglycerides (>200 mg/dL), n-3 PUFAs
(particularly icosapent ethyl 2 ! 2 g daily) ‘should be’
considered in high-risk patients with persistently ele-
vated triglycerides (between 135 and 499 mg/dL)
despite statin treatment. The new recommendations
of n-3 PUFAs are supported by the evidence from
REDUCE-IT trial [39].
Feno!brate (or beza!brate) may be considered in
combination with statins in high-risk patients who are
at LDL-C goal but with persistently elevated triglycer-
ides >200 mg/dL.
In people with high triglycerides, diabetes, obesity
or very low (either naturally occurring or therapeuti-
cally achieved) LDL levels, the guidelines also recom-
mend the use of non-HDL-C because it is a derived
calculated metric which is available with a standard
lipid pro!le at no cost and it is an estimate of the
cholesterol content of all apoB-containing lipoproteins
that cause atherosclerosis. There is also a new recom-
mendation that apoB should be measured for asses-
sing the clinical bene!t of any lipid-lowering therapy
as it is directly proportional to the absolute change in
the apoB-containing lipoprotein concentration. Non-
HDL-C or apoB can be used as an alternative to LDL-C
when LDL-C cannot be calculated (triglycerides
>400 mg/dL).
Also new to these guidelines is the recommenda-
tion that lipoprotein(a) [Lp(a)] should be measured at
least once in each person’s lifetime. Epidemiologic and
Mendelian randomisation studies support that Lp(a) is
causal in ischaemic heart disease [40,41] and thus a risk
modi!er that nuances the ASCVD risk in low,moderate
and high-risk individuals. Speci!cally, persons who
have extreme elevations of Lp(a) above 180 mg/dL
(or >430 nmol/L) may have a lifetime risk of ASCVD
that is equivalent to that observed in patients with FH.
This situation that is twofold more prevalent than FH
may represent a new inherited lipoprotein ASCVD risk
disorder. The new emphasis on Lp(a) is important,
given the fact that novel treatments that are speci!c
to this lipoprotein abnormality are now entering phase
III clinical trials in high and very high-risk patients [42].
Currently, treatment of high Lp(a) is limited to the
PCSK9 inhibitors which have been shown to reduce
levels by 25-30% on average [43,44].
Familial hypercholesterolaemia
Familial hypercholesterolaemia (FH) is an autosomal
dominant lipoprotein disorder characterized by signif-
icant elevation of LDL-C and markedly increased risk of
premature ASCVD. The prevalence of FH is 1/300
(around 40.000 Belgians). Familial hypercholesterolae-
mia (FH) remains under-diagnosed and under-treated
worldwide. Up to 2013 in Belgium, only a fraction of
heterozygous FH carriers have been genetically char-
acterized [45]. Awareness of this disease is thus crucial
for recognizing FH amongst all patients visiting their
doctors or admitted for ASCVD events in hospitals.
Once identi!ed, extended cascade screening in the
family is the best approach to identify and treat as
early as possible (around age 10 years). In Belgium,
several initiatives have been launched these last 5
years to increase the e#ciency of diagnosis such as
the creation of a patient association for FH (www.
Belchol.be) which organized several awareness cam-
paigns and a parliament conference, a consensus
paper on the management of FH in children [46], the
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organization of a strategy to facilitate the detection
and management of FH among patients hospitalized
for an ASCVD event in more than 35 coronary care
units [47] and an ongoing study examining the feasi-
bility of cascade screening with the collaboration of
!eld nurses in our country.
Side e!ects and adherence of lipid-lowering
drugs
During the last years, side e"ects of lipid-lowering
therapy have been overemphasized by the media
and fake news about ‘cholesterol’ has contributed to
a poor adherence to therapy [48]. Roughly 10% of
cardiovascular disease events in Europe could be
attributed to poor adherence and currently, the high-
est poor adherence is for the statin class [49]. This
could become worse because by setting up lower
LDL-C goals the adherence with lifestyle changes and
drug therapy may become even more problematic.
Statins like any other drugs produce side e"ects but
the most relevant are myalgia and diabetes. However,
there have been reports proclaiming that statins
induce Parkinson or Alzheimer disease or whatever
other diseases. These are not based on scienti!c evi-
dence, cause confusion among the public and must be
contradicted [50]. Consensus panels of the EAS have
summarized the problems related to side-e"ects of
statins and how to handle these [48,51].
A low or very low LDL-C level is not dangerous.
Cholesterol is the precursor of vitamin D, corticoster-
oids and gonadal steroids but their metabolism is not
impaired by therapeutic lowering to very low LDL-C
levels. The fact is that an organism does not need
circulating cholesterol in order to function. There are
examples of animals (cholesterol as low as 10 mg/dL in
hippopotamus), of human populations (Tsimani), of
individuals with inherited extremely low cholesterol
(cholesterol as low as 10 mg/dL in homozygotes for
loss of function PCSK9 mutation) and of human new-
borns (cholesterol is 50–70 mg/dL) who develop nor-
mally despite their low level of cholesterol. Another
interesting model for proof of concept is the young
patients who have homozygote familial hypercholes-
terolemia and have no LDL receptor at all in their body.
They have very high LDL cholesterol and their cells
cannot catch LDL from the arteries. Nevertheless,
their organs such as their breasts and their testes/
ovaries develop normally and they are not more sus-
ceptible to Parkinson disease, Alzheimer disease or
cancers.
Conclusions
The concept of LDL-C as a cause of ASCVD is now
clearly demonstrated. It is the basis of the update of
the ESC/EAS guidelines. The current recommendations
consider the targeting of therapy for maximal reduc-
tion events among those who are truly at risk while
limiting the exposure to drugs in the cost in those who
are not at risk. Switching from a risk-based strategy to
a bene!t-based approach is expected to promote sub-
stantial changes in statin eligibility especially in sub-
jects at intermediate CV risk, modifying the
subpopulation to be bene!ted by the treatment [52].
This is clearly the better approach for our patients and
for health-care policy.
The fundamental next steps are the appropriate
implementation by clinicians in their practice, together
with ensuring treatment adherence by patients. Most
drugs are now generic, which facilitate considerably
the prescription of statin, ezetimibe and their combi-
nations. The only limitation is for PCSK9 inhibitors
which remain expensive and are not reimbursed in
Belgium in all clinical situations recommended in the
new ESC/EAS guidelines. So far, reimbursements are
limited only to patients with familial hypercholestero-
lemia in addition to conventional treatments (statin
and ezetimibe). Discussions within INAMI/RIZIV are
underway to extend their use to other indications
such as post-acute coronary syndrome if LDL-C levels
are not yet su#ciently lowered under optimal
treatment.
It is important that the attitude chosen to correct
dyslipidemia is fully discussed with the patient. If it is
up to the physician to scrupulously estimate the risks,
bene!ts and legitimacy of treatment or non-treatment
(in light of the international recommendations and
local reimbursement rules) and to propose the thera-
peutic options, it is up to the patient to decide on the
choice of treatment (or non-treatment) based on the
information clearly provided by the doctor. In this
regard, it is essential to discuss with them about the
issues involved in each therapeutic choice, both in
terms of bene!ts and in terms of constraints and risks
of side e"ects. It is only with this spirit that patients will
be keen to follow their treatment.
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